Pha-665752

Pha-665752

SCHEMBL93656

Cc1[nH]c(C=C2C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCCC1CN1CCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 1.00
FGFR1 P11362 9/20 1.00
PDGFRB P09619 9/20 1.00
MET P08581 7/20 1.00
SRC P12931 6/20 1.00
LCK P06239 4/20 1.00
YES1 P07947 4/20 1.00
CDK2 P24941 2/20 1.00
PTK2B Q14289 2/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
TDP1 Q9NUW8 2/20 1.00
KIT P10721 2/20 1.00
EGFR P00533 2/20 1.00
ALK Q9UM73 2/20 1.00
PLK4 O00444 1/20 1.00
RIOK3 O14730 1/20 1.00
CASK O14936 1/20 1.00
GAK O14976 1/20 1.00
DCLK1 O15075 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pha-665752 SCHEMBL29376386 1.00 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL93657 1.00 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL93655 1.00 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL140412 1.00 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL93654 1.00 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL15639801 0.99 KDR (0.99) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL15639803 0.99 KDR (0.99) KDRFGFR1PDGFRBMETSRC
SCHEMBL23691031 0.97 KDR (0.94) KDRFGFR1PDGFRBMETSRC
SCHEMBL143795 0.96 KDR (0.93) KDRFGFR1PDGFRBMETSRC
SCHEMBL147331 0.95 KDR (0.91) KDRFGFR1PDGFRBMETSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2425830-A1 Synergistic drug combination for the treatment of cancer Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2012-03-07 EP claimed
CN-113164480-B Pharmaceutical composition for treating diffuse gastric cancer 学校法人金泽医科大学 2023-11-28 CN disclosed
EP-3296905-B1 METHOD FOR IDENTIFYING NEW MARKERS ALACRIS THERANOSTICS GMBH (DE) 2023-11-08 EP disclosed
CN-113164480-A Pharmaceutical composition for treating diffuse gastric cancer 学校法人金泽医科大学 2021-07-23 CN disclosed
CN-104762371-B Biomarkers for predicting or monitoring the efficacy of c-Met inhibitors 三星电子株式会社 2021-03-09 CN disclosed
EP-3296905-A1 METHOD FOR IDENTIFYING NEW MARKERS Alacris Theranostics GmbH (DE) 2018-03-21 EP disclosed
EP-2425830-A1 Synergistic drug combination for the treatment of cancer Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2012-03-07 EP disclosed